The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Second Cancer Risk After Chemotherapy for Hodgkin's Lymphoma: A Collaborative British Cohort Study
Open accessAbstract
Purpose: We investigated the long-term risk of second primary malignancy after chemotherapy for Hodgkin's lymphoma (HL) in a much larger cohort than any yet published, to our knowledge. Patients and Methods: We followed 5,798 patients with HL treated with chemotherapy in Britain from 1963 to 2001—of whom 3,432 also received radiotherapy—to assess second primary malignancy risks compared with general population-based expectations. Results: Second malignancies occurred in 459 cohort members. Relative risk (RR) of second cancer was raised after chemotherapy alone (RR, 2.0; 95% CI, 1.7 to 2.4) but was much lower than after combined modalities (RR, 3.9; 95% CI, 3.5 to 4.4). After chemotherapy alone, there were significantly raised risks of lung cancer, non-HL, and leukemia, each contributing approximately equal absolute excess risk. After combined modalities, there were raised risks of these and several other cancers. Second cancer risk peaked 5 to 9 years after chemotherapy alone, but it remained raised for 25 years and longer after combined modalities. Risk was raised after each common chemotherapy regimen except, based on limited numbers and follow-up, adriamycin, bleomycin, vinblastine, and dacarbazine. The age and time-course relations of lung cancer differed between chemotherapy alone and combined modalities. Conclusion: Although chemotherapy alone leads to raised risk of second malignancy, this risk is lower and affects fewer anatomic sites than that after combined modalities, and it is slight if at all after 15 years follow-up. The mechanism of lung cancer etiology may differ between chemotherapy and radiotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bone Sarcomas Linked to Radiotherapy and Chemotherapy in Children
Tucker, M. A., D'Angio, G. J., Boice, J. D., Strong, L. C., Li, F. P., Stovall, M., Stone, B. J., Green, D. M., Lombardi, F., Newton, W., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198709033171002 · Cited by 765
Cited by
Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma
Schaapveld, M., Aleman, B. M. P., van Eggermond, A. M., Janus, C. P. M., Krol, A. D. G., van der Maazen, R. W. M., Roesink, J., Raemaekers, J. M. M., de Boer, J. P., Zijlstra, J. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505949 · Cited by 637
Radiation induced secondary malignancies: a review article
Dracham, C. B., Shankar, A., & Madan, R. (2018) · Radiation Oncology Journal · doi:10.3857/roj.2018.00290 · Cited by 349
Second Malignant Neoplasms: Assessment and Strategies for Risk Reduction
Wood, M. E., Vogel, V., Ng, A., Foxhall, L., Goodwin, P., & Travis, L. B. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.8681 · Cited by 323
Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors
Travis, L. B., Wahnefried, W. D., Allan, J. M., Wood, M. E., & Ng, A. K. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.41 · Cited by 264
Cancer risks in patients treated with growth hormone in childhood: the SAGhE European cohort study
Swerdlow, A. J., Cooke, R., Beckers, D., Borgström, B., Butler, G., Carel, J.-C., Cianfarani, S., Clayton, P., Coste, J., Deodati, A., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2046 · Cited by 153
“Melanoma, however, is not a tumor usually raised after radiotherapy and chemotherapy, although it has been in at least one instance (31).”
Background
Metadata
- Authors
- Swerdlow, A. J., Higgins, C. D., Smith, P., Cunningham, D., Hancock, B. W., Horwich, A., Hoskin, P. J., Lister, T. A., Radford, J. A., Rohatiner, A. Z. S., & Linch, D. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-11-01
- Volume
- 29
- Issue
- 31
- Pages
- 4096-4104
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2121676620
- Cited by
- 222
- References
- 1
- FWCI
- 10.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Second Cancer Risk After Chemotherapy for Hodgkin's Lymphoma: A Collaborative British Cohort Study. https://app.cochat.ai/papers/10.1200/jco.2011.34.8268
- The paper
- Swerdlow, A. J., Higgins, C. D., Smith, P., Cunningham, D., Hancock, B. W., Horwich, A., Hoskin, P. J., Lister, T. A., Radford, J. A., Rohatiner, A. Z. S., & Linch, D. C. (2011). Second Cancer Risk After Chemotherapy for Hodgkin's Lymphoma: A Collaborative British Cohort Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.34.8268
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.